![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1672685
¼¼°èÀÇ »ý¹°Á¦Á¦ ½ÃÀå : Á¦Ç°º°, ÀǾàǰ ºÐ·ùº°, Åõ¿© °æ·Îº°, ±¸ÀÔ Çüź°, À¯Åë ä³Îº°, Áö¿ªº°Biologics Market, By Product, By Drug Classification, By Route of Administration, By Mode of Purchase, By Distribution Channel,By Geography |
¼¼°è »ý¹°Á¦Á¦ ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 5¾ï 7,750¸¸ ´Þ·¯, 2032³â¿¡´Â 11¾ï 6,980¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â 10.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ »ó¼¼ ³»¿ë | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 5¾ï 7,750¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR | 10.60% | 2032³â °¡Ä¡ ¿¹Ãø | 11¾ï 6,980¸¸ ´Þ·¯ |
»ý¹°ÇÐÀûÁ¦Á¦¶õ Àΰ£ÀÇ Áúº´À» ¿¹¹æ, Ä¡·á, Ä¡À¯Çϱâ À§ÇØ »ç¿ëµÇ´Â »ý¹°Ã¼¿¡¼ ¸¸µé¾îÁø ÀǾàǰÀ» ¸»ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¹é½Å, Ç÷¾×¼ººÐ, ¾Ë·¹¸£°Õ, ü¼¼Æ÷, À¯ÀüÀÚÄ¡·áÁ¦, Á¶Á÷, ÀçÁ¶ÇÕ Ä¡·á¿ë ´Ü¹éÁú µîÀÌ Æ÷ÇԵ˴ϴÙ. ´Ù¾çÇÑ Áúº´¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡¿Í ÇÔ²² Àü ¼¼°èÀûÀ¸·Î ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. »ý¸í°øÇÐÀÇ ±Þ¼ÓÇÑ Çõ½Å°ú ¹ßÀüÀ¸·Î ¾ÈÀü¼º, À¯È¿¼º, ÀÛ¿ë Æ¯À̼ºÀÌ °³¼±µÈ »õ·Î¿î »ý¹°Á¦Á¦ÀÇ °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¾Ï, ·ù¸¶Æ¼½º Áúȯ, ÀÚ°¡¸é¿ªÁúȯ µî »ý¸íÀ» À§ÇùÇÏ´Â ¿©·¯ Áúȯ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú »ý¹°Á¦Á¦ÀÇ »ó¾÷È È®´ë´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ Àü ¼¼°èÀûÀÎ È®»ê°ú ¹ÙÀÌ¿ÀÀǾàǰ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÇコÄɾî ÁöÃâ Áõ°¡°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ü¹éÁú ±â¹Ý ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÷´Ü ¹ÙÀÌ¿ÀÀǾàǰÀÇ ½Å¼ÓÇÑ ½ÂÀÎ, ½Å±Ô ¹ÙÀÌ¿ÀÀǾàǰ Èĺ¸¹°ÁúÀÇ °·ÂÇÑ ÆÄÀÌÇÁ¶óÀεµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹× ǰÁú ºÐ¼® ºÐ¾ßÀÇ ²÷ÀÓ¾ø´Â ±â¼ú ¹ßÀüÀº »ó¾÷Àû ±Ô¸ðÀÇ ¹ÙÀÌ¿À ÀǾàǰÀ» ºñ¿ë È¿À²ÀûÀ¸·Î »ý»êÇÒ ¼ö ÀÖ´Â °í¼öÀ² »ý»ê Ç÷§ÆûÀÇ °³¹ßÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¹ÙÀÌ¿À Á¦Á¶ ½Ã¼³ ¼³Ä¡¿¡ ÇÊ¿äÇÑ ¸·´ëÇÑ ¼³ºñ ÅõÀÚ, ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ, º¹ÀâÇÑ »ý¹°ÇÐÀû ºÐÀÚÀÇ º¹À⼺ µîÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ßÀÇ Àå¾Ö¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä« µî ½ÅÈï±¹ ½ÃÀåÀº ÀÌÇØ°ü°èÀڵ鿡°Ô »õ·Î¿î ½ÃÀå °³Ã´°ú ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎÀ» »ó¼âÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ »ý¹°Á¦Á¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í CAGR(¿¬Æò±Õ ¼ºÀå·ü)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â ¿¡ÇÁ È£ÇÁ¸¸ ¶ó ·Î½´, ¾Öºêºñ, ¾ÏÁ¨, Á¸½¼¾ØµåÁ¸½¼ ¼ºñ½º, ¸ÓÅ©, ÈÀÌÀÚ, »ç³ëÇÇ, ±æ¸®¾îµå »çÀ̾ð½º, ³ë¹ÙƼ½º, ºê¸®½ºÅç ¸¶À̾ ½ºÄûºê, ¸®Á¦³×·Ð, ´ÙÄÉ´Ù¾àǰ°ø¾÷, ¹ÙÀÌ¿À. Á¨, À϶óÀÌ ¸±¸® ¾Ø ÄÄÆÛ´Ï, ¼¿Æ®¸®¿ÂÇコÄÉ¾î µîÀÌ Æ÷ÇԵ˴ϴÙ.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
Global Biologics Market is estimated to be valued at USD 577.5 Mn in 2025 and is expected to reach USD 1,169.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 577.5 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 10.60% | 2032 Value Projection: | USD 1,169.8 Mn |
Biologics refers to medicines created from living organisms that are used to prevent, treat, and cure human diseases. These include vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Increasing prevalence of chronic diseases worldwide coupled with rising elderly population prone to various illnesses can boost demand for biologics. Rapid innovations and advancements in biotechnology have enabled development of novel biologic agents with improved safety, efficacy and specificity of action. This has expanded treatment options for several life-threatening conditions such as cancer, rheumatic disorders, and autoimmune diseases. Growing regulatory approvals and commercialization of biologics can drive the market growth.
Global biologics market growth is driven by growing prevalence of chronic diseases worldwide such as diabetes, cancer, cardiovascular diseases along with rising healthcare expenditure on biopharmaceutical R&D. Increasing demand for protein-based drugs, rapid approvals of advanced biologics and strong pipeline of novel biologic candidates can also drive the market growth. Constant technological advancements in bioprocessing and quality analytics enables development of high-yield production platforms conducive for cost-effective manufacturing of biologics at commercial scale. However, factors such as high capital investment needs for setting up bio-manufacturing facilities, stringent regulatory norms, and complexity of biological molecules poses challenges in biosimilar development. Emerging markets across developing regions such as Asia Pacific and Latin America offer lucrative opportunities for stakeholders to tap into new geographic territories and offset restraint impact.
Key Features of the Study
This report provides in-depth analysis of the global biologics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global biologics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Eli Lilly and Company, and Celltrion Healthcare Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics market